sofosbuvir + velpatasvir + voxilaprevir at a glance
Medicine class
Pangenotypic direct-acting antiviral combination.
Licensed population
People aged 12 years or older who weigh at least 30 kg and have chronic hepatitis C.
Administration
Swallow whole with food; do not chew or crush because the tablet is bitter.
Specialist oversight
Treatment should be started and monitored by a clinician experienced in hepatitis C care.
What is sofosbuvir + velpatasvir + voxilaprevir used for?
Its UK licence covers:
Treatment of chronic hepatitis C virus infection in people aged 12 years or older who weigh at least 30 kg.
Use across hepatitis C genotypes, including in people with previous direct-acting antiviral exposure, where liver function and other clinical factors are suitable.
How does sofosbuvir + velpatasvir + voxilaprevir work?
Sofosbuvir stops the NS5B polymerase from copying viral RNA. Velpatasvir blocks NS5A, needed for viral replication and assembly, while voxilaprevir blocks the NS3/4A protease needed to process viral proteins. Together, these actions suppress hepatitis C replication.
sofosbuvir + velpatasvir + voxilaprevir preparations and strengths
Tablet
Route: Oral
Strengths: 400 mg + 100 mg + 100 mg
How to take sofosbuvir + velpatasvir + voxilaprevir
Follow the specialist team's instructions.
Take the tablet with food.
Swallow it whole; do not split, chew or crush it.
Tell the treatment team about prescription medicines, non-prescription products and herbal remedies before starting anything new.
sofosbuvir + velpatasvir + voxilaprevir side effects
Common or expected effects
- Headache
- Diarrhoea
- Nausea
- Abdominal pain
- Reduced appetite
- Vomiting
- Rash
- Muscle pain
- Raised bilirubin on blood testing
Get urgent medical advice
- Swelling of the face, lips, tongue or throat, suggesting angioedema
- A widespread severe rash with peeling skin or blisters involving the mouth, eyes or genitals
- Severe slowing of the heartbeat or heart block, particularly with current or recent amiodarone
sofosbuvir + velpatasvir + voxilaprevir in pregnancy
Human pregnancy information is limited. The combination is not recommended during pregnancy as a precaution. Discuss pregnancy, suspected pregnancy or plans to conceive promptly with the hepatitis specialist or prescriber.
sofosbuvir + velpatasvir + voxilaprevir while breastfeeding
It is unknown how much of the active substances enters human milk, and a risk to the infant cannot be excluded. The product should not be used while breastfeeding; feeding and treatment options require specialist discussion.
sofosbuvir + velpatasvir + voxilaprevir interactions
A complete interaction check is essential because some combinations are contraindicated or may reduce antiviral effectiveness.
Carbamazepine, phenobarbital or phenytoin
Strong induction can substantially reduce antiviral exposure; concomitant use is contraindicated.
Rifampicin or rifabutin
These can substantially reduce antiviral exposure; concomitant use is contraindicated.
St John’s wort
It can reduce antiviral concentrations and must not be taken with this combination.
Common questions about sofosbuvir + velpatasvir + voxilaprevir
Answers are fully visible for fast scanning and source review.
What is sofosbuvir + velpatasvir + voxilaprevir used for?
It treats chronic hepatitis C in licensed adolescents and adults. Specialists may select it when previous direct-acting antiviral treatment has not cleared the infection.
How does sofosbuvir + velpatasvir + voxilaprevir differ from sofosbuvir + velpatasvir?
It adds voxilaprevir, which blocks the viral NS3/4A protease, alongside NS5B and NS5A inhibition.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.